-
Gastro-Intestinal Symptoms in Palliative Care Patients Curr. Oncol. (IF 2.6) Pub Date : 2024-04-21 Golda Elisa Tradounsky
This review of the palliation of various gastro-intestinal (GI) symptoms encountered in cancer patients is by no means exhaustive. Frequent symptoms such as constipation, nausea and vomiting, bowel obstructions, ascites and bleeds will be discussed, focusing on their assessment and most importantly, how to control the associated symptoms. All of these symptoms and GI complications can significantly
-
Quality-of-Life Assessment in Pediatric Advanced Cancer: Development of the Patient-Reported Outcome Measure Advance QoL Curr. Oncol. (IF 2.6) Pub Date : 2024-04-19 Lye-Ann Robichaud, Julie Felipe, Michel Duval, Bruno Michon, Marianne Olivier-D’Avignon, Sébastien Perreault, Mathias Tyo-Gomez, Marc-Antoine Marquis, Serge Sultan
A recent measure was developed to assess the Quality of Life (QoL) of young people with advanced cancer and is available for parents and professionals (Advance QoL). The present study aimed to elaborate self-reported versions for children and adolescents with advanced cancer. We adopted a four-phase research plan: (1) to elaborate the Advance QoL questionnaire for youth (8–12 and 13–18 years old) with
-
Impact of Pregnancy on Breast Cancer Features and Prognosis Curr. Oncol. (IF 2.6) Pub Date : 2024-04-19 Valentina E. Bounous, Carola Minella, Luca Fuso, Silvia Actis, Greta Petroni, Luca G. Sgrò, Martina Borghese, Nicoletta Tomasi Cont, Riccardo Ponzone, Annamaria Ferrero
Background: pregnancy-associated breast cancer (PABC) affects one in 3000 pregnancies, often presenting with aggressive features. Methods: We retrospectively evaluated a cohort of 282 young BC patients (≤45 years old) treated between 1995 and 2019, dividing them into three groups: nulliparous women, women with PABC (diagnosed within 2 years since last pregnancy) and women with BC diagnosed > 2 years
-
Antibody–Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data Curr. Oncol. (IF 2.6) Pub Date : 2024-04-19 Prathana Nathan, Adnan Rajeh, Meh Noor, Gabriel Boldt, Ricardo Fernandes
The treatment landscape of genitourinary cancers has significantly evolved over the past few years. Renal cell carcinoma, bladder cancer, and prostate cancer are the most common genitourinary malignancies. Recent advancements have produced new targeted therapies, particularly antibody–drug conjugates (ADCs), due to a better understanding of the underlying oncogenic factors and molecular mechanisms
-
The Impact of the Pandemic on the Quality of Colorectal and Anal Cancer Care, and 2-Year Clinical Outcomes Curr. Oncol. (IF 2.6) Pub Date : 2024-04-19 Melanie Powis, Rinku Sutradhar, Simron Singh, Shabbir Alibhai, Saidah Hack, Abed Baiad, Kevin Chen, Huaqi Li, Zuhal Mohmand, Monika K. Krzyzanowska
We undertook a retrospective study to compare the quality of care delivered to a cohort of newly diagnosed adults with colon, rectal or anal cancer during the early phase of COVID-19 (02/20–12/20) relative to the same period in the year prior (the comparator cohort), and examine the impact of the pandemic on 2-year disease progression and all-cause mortality. We observed poorer performance on a number
-
Deep Learning Prediction of Axillary Lymph Node Metastasis in Breast Cancer Patients Using Clinical Implication-Applied Preprocessed CT Images Curr. Oncol. (IF 2.6) Pub Date : 2024-04-18 Tae Yong Park, Lyo Min Kwon, Jini Hyeon, Bum-Joo Cho, Bum Jun Kim
Background: Accurate detection of axillary lymph node (ALN) metastases in breast cancer is crucial for clinical staging and treatment planning. This study aims to develop a deep learning model using clinical implication-applied preprocessed computed tomography (CT) images to enhance the prediction of ALN metastasis in breast cancer patients. Methods: A total of 1128 axial CT images of ALN (538 malignant
-
Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients Curr. Oncol. (IF 2.6) Pub Date : 2024-04-17 Sophie Laroumagne, Julie Tronchetti, Hervé Dutau, Philippe Astoul
Maintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with
-
An Evaluation of Racial and Ethnic Representation in Research Conducted with Young Adults Diagnosed with Cancer: Challenges and Considerations for Building More Equitable and Inclusive Research Practices Curr. Oncol. (IF 2.6) Pub Date : 2024-04-15 Sharon H. J. Hou, Fiona S. M. Schulte, Anika Petrella, Joshua Tulk, Amanda Wurz, Catherine M. Sabiston, Jackie Bender, Norma D’Agostino, Karine Chalifour, Geoff Eaton, Sheila N. Garland
The psychosocial outcomes of adolescents and young adults (AYAs) diagnosed with cancer are poorer compared to their peers without cancer. However, AYAs with cancer from diverse racial and ethnic groups have been under-represented in research, which contributes to an incomplete understanding of the psychosocial outcomes of all AYAs with cancer. This paper evaluated the racial and ethnic representation
-
Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery Curr. Oncol. (IF 2.6) Pub Date : 2024-04-15 Hala Muaddi, LaDonna Kearse, Susanne Warner
With an overall 5-year survival rate of 12%, pancreas ductal adenocarcinoma (PDAC) is an aggressive cancer that claims more than 50,000 patient lives each year in the United States alone. Even those few patients who undergo curative-intent resection with favorable pathology reports are likely to experience recurrence within the first two years after surgery and ultimately die from their cancer. We
-
Survival Outcome Prediction in Glioblastoma: Insights from MRI Radiomics Curr. Oncol. (IF 2.6) Pub Date : 2024-04-14 Effrosyni I. Styliara, Loukas G. Astrakas, George Alexiou, Vasileios G. Xydis, Anastasia Zikou, Georgios Kafritsas, Spyridon Voulgaris, Maria I. Argyropoulou
Background: Extracting multiregional radiomic features from multiparametric MRI for predicting pretreatment survival in isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients is a promising approach. Methods: MRI data from 49 IDH wild-type glioblastoma patients pre-treatment were utilized. Diffusion and perfusion maps were generated, and tumor subregions segmented. Radiomic features were
-
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review Curr. Oncol. (IF 2.6) Pub Date : 2024-04-12 Diego Parrao, Nemecio Lizana, Catalina Saavedra, Matías Larrañaga, Carolina B. Lindsay, Ignacio F. San Francisco, Juan Cristóbal Bravo
Bladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant
-
The Level of Agreement between Self-Assessments and Examiner Assessments of Melanocytic Nevus Counts: Findings from an Evaluation of 4548 Double Assessments Curr. Oncol. (IF 2.6) Pub Date : 2024-04-13 Olaf Gefeller, Isabelle Kaiser, Emily M. Brockmann, Wolfgang Uter, Annette B. Pfahlberg
Cutaneous melanoma (CM) is a candidate for screening programs because its prognosis is excellent when diagnosed at an early disease stage. Targeted screening of those at high risk for developing CM, a cost-effective alternative to population-wide screening, requires valid procedures to identify the high-risk group. Self-assessment of the number of nevi has been suggested as a component of such procedures
-
Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia Curr. Oncol. (IF 2.6) Pub Date : 2024-04-09 Marta Parera Roig, David Compte Colomé, Gemma Basagaña Colomer, Emilia Gabriela Sardo, Mauricio Alejandro Tournour, Silvia Griñó Fernández, Arturo Ivan Ominetti, Emma Puigoriol Juvanteny, José Luis Molinero Polo, Daniel Badia Jobal, Nadia Espejo-Herrera
Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital
-
The Evaluation and Management of Lung Metastases in Patients with Giant Cell Tumors of Bone in the Denosumab Era Curr. Oncol. (IF 2.6) Pub Date : 2024-04-09 Giulia Trovarelli, Arianna Rizzo, Mariachiara Cerchiaro, Elisa Pala, Andrea Angelini, Pietro Ruggieri
Giant cell tumor of bone (GCTB) is characterized by uncertain biological behavior due to its local aggressiveness and metastasizing potential. In this study, we conducted a meta-analysis of the contemporary literature to evaluate all management strategies for GCTB metastases. A combination of the terms “lung metastases”, “giant cell tumor”, “bone”, “treatment”, and “oncologic outcomes” returned 133
-
Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data Curr. Oncol. (IF 2.6) Pub Date : 2024-04-09 Ruth Moulson, Guillaume Feugère, Tracy S. Moreira-Lucas, Florence Dequen, Jessica Weiss, Janet Smith, Christine Brezden-Masley
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−) advanced/metastatic breast cancer (ABC/MBC) in first line (1L), but little is known about their real-world use and clinical outcomes long-term, in Canada. This study used Pentavere’s previously validated artificial intelligence (AI)
-
Prehabilitation in Adults Undergoing Cancer Surgery: A Comprehensive Review on Rationale, Methodology, and Measures of Effectiveness Curr. Oncol. (IF 2.6) Pub Date : 2024-04-09 Carlos E. Guerra-Londono, Juan P. Cata, Katherine Nowak, Vijaya Gottumukkala
Cancer surgery places a significant burden on a patients’ functional status and quality of life. In addition, cancer surgery is fraught with postoperative complications, themselves influenced by a patient’s functional status. Prehabilitation is a unimodal or multimodal strategy that aims to increase a patient’s functional capacity to reduce postoperative complications and improve postoperative recovery
-
Preoperative Direct Puncture Embolization of Castleman Disease of the Parotid Gland: A Case Report Curr. Oncol. (IF 2.6) Pub Date : 2024-04-04 Alessandro Pedicelli, Pietro Trombatore, Andrea Bartolo, Arianna Camilli, Esther Diana Rossi, Luca Scarcia, Andrea M. Alexandre
Background: Castleman disease (CD) is an uncommon benign lymphoproliferative disease characterized by hypervascular lymphoid hyperplasia. We present a unique case of unicentric CD of the parotid gland treated by preoperative direct puncture embolization. Case presentation: A 27-year-old female patient was admitted for a right neck mass. Ultrasound examination and MRI scan documented a hypervascular
-
Interdisciplinary Collaboration in Head and Neck Cancer Care: Optimizing Oral Health Management for Patients Undergoing Radiation Therapy Curr. Oncol. (IF 2.6) Pub Date : 2024-04-07 Tugce Kutuk, Ece Atak, Alessandro Villa, Noah S. Kalman, Adeel Kaiser
Radiation therapy (RT) plays a crucial role in the treatment of head and neck cancers (HNCs). This paper emphasizes the importance of effective communication and collaboration between radiation oncologists and dental specialists in the HNC care pathway. It also provides an overview of the role of RT in HNC treatment and illustrates the interdisciplinary collaboration between these teams to optimize
-
Innovation and Discovery: A 30-Year Journey in Advancing Cancer Care Curr. Oncol. (IF 2.6) Pub Date : 2024-04-08 Shahid Ahmed
Since the inaugural issue of Current Oncology was published 30 years ago, we have witnessed significant advancements in cancer research and care [...]
-
Current Concepts in the Treatment of Giant Cell Tumor of Bone: An Update Curr. Oncol. (IF 2.6) Pub Date : 2024-04-08 Shinji Tsukamoto, Andreas F. Mavrogenis, Tomoya Masunaga, Kanya Honoki, Hiromasa Fujii, Akira Kido, Yasuhito Tanaka, Costantino Errani
Curettage is recommended for the treatment of Campanacci stages 1–2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible
-
Symptom Burden and Time from Symptom Onset to Cancer Diagnosis in Patients with Early-Onset Colorectal Cancer: A Multicenter Retrospective Analysis Curr. Oncol. (IF 2.6) Pub Date : 2024-04-08 Victoria A. Baronas, Arif A. Arif, Eric Bhang, Gale K. Ladua, Carl J. Brown, Fergal Donnellan, Sharlene Gill, Heather C. Stuart, Jonathan M. Loree
Background: The incidence of colorectal cancer (CRC) is decreasing in individuals >50 years due to organised screening but has increased for younger individuals. We characterized symptoms and their timing before diagnosis in young individuals. Methods: We identified all patients diagnosed with CRC between 1990–2017 in British Columbia, Canada. Individuals <50 years (n = 2544, EoCRC) and a matched cohort
-
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine Curr. Oncol. (IF 2.6) Pub Date : 2024-04-02 Mariana Pilon Capella, Khashayar Esfahani
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now become the new standards of care in cancer therapy. These include novel antibody-drug conjugates, chimeric antigen receptor T cell therapies (CAR-T), and bispecific
-
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration Curr. Oncol. (IF 2.6) Pub Date : 2024-04-01 Pam Takhar, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E. Mercer, Avram Denburg, Caroline Muñoz, Mina Tadrous, Ambica Parmar, Francois Dionne, Darryl Boehm, Carole Chambers, Erica Craig, Maureen Trudeau, Matthew C. Cheung, Joanne Houlihan, Valerie McDonald, Petros Pechlivanoglou, Marianne Taylor, Eric Wasylenko, Wiesława Dominika Wranik, Kelvin K. W. Chan
Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting of seven criteria evaluating the importance and feasibility of conducting potential real-world evidence (RWE) studies aimed at addressing uncertainties
-
A Rare Early-Onset Fatal Complication after Transarterial Chemoembolization: A Case Report and Review of the Literature Curr. Oncol. (IF 2.6) Pub Date : 2024-04-03 Monika Péčová, Jakub Benko, Martin Jozef Péč, Jakub Jurica, Simona Horná, Tomáš Bolek, Tatiana Hurtová, Ján Sýkora, Kamil Zeleňák, Matej Samoš, Juraj Sokol
Transarterial chemoembolization (TACE) is a minimally invasive treatment for liver cancer, often employed as a bridging therapy or destination treatment for non-operable cases. This case report discusses an 82-year-old woman with a large hepatocellular carcinoma (HCC) who underwent elective TACE due to the high surgical risk associated with her tumor size. Unexpectedly, the patient experienced liver
-
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape Curr. Oncol. (IF 2.6) Pub Date : 2024-04-03 Daniel Karel, Claire Valburg, Navitha Woddor, Victor E. Nava, Anita Aggarwal
Myelodysplastic neoplasms (MDS) are a heterogenous clonal disorder of hemopoietic stem cells characterized by cytomorphologic dysplasia, ineffective hematopoiesis, peripheral cytopenias and risk of progression to acute myeloid leukemia (AML). Our understanding of this disease has continued to evolve over the last century. More recently, prognostication and treatment have been determined by cytogenetic
-
The Efficacy of Fat Grafting on Treating Post-Mastectomy Pain with and without Breast Reconstruction: A Systematic Review and Meta-Analysis Curr. Oncol. (IF 2.6) Pub Date : 2024-04-04 Jeffrey Chen, Abdulrahman A. Alghamdi, Chi Yi Wong, Muna F. Alnaim, Gabriel Kuper, Jing Zhang
Post-mastectomy pain syndrome (PMPS), characterized by persistent pain lasting at least three months following mastectomy, affects 20–50% of breast surgery patients, lacking effective treatment options. A review was conducted utilizing EMBASE, MEDLINE, and all evidence-based medicine reviews to evaluate the effect of fat grafting as a treatment option for PMPS from database inception to 29 April 2023
-
True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations—Brief Report Curr. Oncol. (IF 2.6) Pub Date : 2024-04-05 Michèle Hoffmann, Yara Banz, Jörg Halter, Jacqueline Schoumans, Joëlle Tchinda, Ulrike Bacher, Thomas Pabst
Donor cell leukemia (DCL) is a rare complication after allogeneic hematopoietic stem cell transplantation (HSCT) accounting for 0.1% of relapses and presenting as secondary leukemia of donor origin. Distinct in phenotype and cytogenetics from the original leukemia, DCL’s clinical challenge lies in its late onset. Its origin is affected by donor cell anomalies, transplant environment, and additional
-
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management Curr. Oncol. (IF 2.6) Pub Date : 2024-04-05 Cody R. Criss, Mina S. Makary
Neuroendocrine tumors (NETs) are a heterogeneous class of cancers, predominately occurring in the gastroenteropancreatic system, which pose a growing health concern with a significant rise in incidence over the past four decades. Emerging from neuroendocrine cells, these tumors often elicit paraneoplastic syndromes such as carcinoid syndrome, which can manifest as a constellation of symptoms significantly
-
Radiological and Not Clinical Variables Guide the Surgical Plan in Patients with Glioblastoma Curr. Oncol. (IF 2.6) Pub Date : 2024-04-01 Carla Martín-Abreu, Helga Fariña-Jerónimo, Julio Plata-Bello
Background and Purpose: The extent of resection is the most important prognostic factor in patients with glioblastoma. However, the factors influencing the decision to perform a biopsy instead of maximal resection have not been clearly established. The aim of this study was to analyze the factors associated with the intention to achieve maximal resection in glioblastoma patients. Methods: A retrospective
-
High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment Curr. Oncol. (IF 2.6) Pub Date : 2024-04-02 Gregor Vivod, Sebastjan Merlo, Nina Kovacevic
Background: Due to the rarity of ovarian cancer diagnosed during pregnancy, the literature on the treatment of subtypes of epithelial ovarian cancer in pregnancy is sparse. The aim of our review was to analyze cases of high-grade serous ovarian cancer in pregnancy. Methods: The PubMed and Scopus databases were searched for relevant articles published in English between January 2000 and December 2023
-
Determining the Need for Metastatic Staging in Patients with Bilateral Breast Cancers Curr. Oncol. (IF 2.6) Pub Date : 2024-04-02 Veronica Siton Alcantara, Sut Mo Zachary Chan, Fuh Yong Wong, John Carson Allen, Geok Hoon Lim
Introduction: Bilateral breast cancers (BBC) diagnosed at an interval apart are uncommon. While metastatic staging guidelines are established in patients with unilateral breast cancer, its role in BBC diagnosed at an interval apart is unclear. We aim to identify the subgroup who would benefit from metastatic staging at contralateral cancer diagnosis. Methods: Eligible patients were divided into three
-
Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence Curr. Oncol. (IF 2.6) Pub Date : 2024-04-02 Ruth Moulson, Jennifer Law, Adrian Sacher, Geoffrey Liu, Frances A. Shepherd, Penelope Bradbury, Lawson Eng, Sandra Iczkovitz, Erica Abbie, Julia Elia-Pacitti, Emmanuel M. Ewara, Viktoriia Mokriak, Jessica Weiss, Christopher Pettengell, Natasha B. Leighl
Real-world evidence for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada is limited. This study’s objective was to use previously validated DARWENTM artificial intelligence (AI) to extract data from electronic heath records of patients with non-squamous NSCLC at University Health Network (UHN) to describe EGFR mutation prevalence, treatment patterns, and outcomes. Of
-
The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review Curr. Oncol. (IF 2.6) Pub Date : 2024-04-03 Eugeniy Smorodin, Valentin Chuzmarov, Toomas Veidebaum
Melatonin is a multifunctional hormone regulator that maintains homeostasis through circadian rhythms, and desynchronization of these rhythms can lead to gastrointestinal disorders and increase the risk of cancer. Preliminary clinical studies have shown that exogenous melatonin alleviates the harmful effects of anticancer therapy and improves quality of life, but the results are still inconclusive
-
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance Curr. Oncol. (IF 2.6) Pub Date : 2024-04-03 Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, Avrosina Kamel, Ariel Liberchuk, Andrew L. Wolfe
KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRAS, including small molecule compounds targeting specific KRAS mutations, pan-KRAS inhibitors, PROTACs
-
Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors Curr. Oncol. (IF 2.6) Pub Date : 2024-03-30 Emma Titmuss, Irene S. Yu, Erin D. Pleasance, Laura M. Williamson, Karen Mungall, Andrew J. Mungall, Daniel J. Renouf, Richard Moore, Steven J. M. Jones, Marco A. Marra, Janessa J. Laskin, Kerry J. Savage
Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations. However, patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity. There is limited information on whether the presence of specific germline mutations may highlight those at elevated risk of irAEs. We evaluated
-
Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Shamim Mortuza, Benjamin Chin-Yee, Tyler E. James, Ian H. Chin-Yee, Benjamin D. Hedley, Jenny M. Ho, Lalit Saini, Alejandro Lazo-Langner, Laila Schenkel, Pratibha Bhai, Bekim Sadikovic, Jonathan Keow, Nikhil Sangle, Cyrus C. Hsia
Myelodysplastic neoplasms (MDS) with ring sideroblasts (RS) are diagnosed via bone marrow aspiration in the presence of either (i) ≥15% RS or (ii) 5–14% RS and an SF3B1 mutation. In the MEDALIST trial and in an interim analysis of the COMMANDS trial, lower-risk MDS-RS patients had decreased transfusion dependency with luspatercept treatment. A total of 6817 patients with suspected hematologic malignancies
-
The Canadian Breast Cancer Symposium 2023 Meeting Report Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Tulin Cil, Jean-François Boileau, Stephen Chia, MJ DeCoteau, Katarzyna J. Jerzak, Anne Koch, Nancy Nixon, May Lynn Quan, Amanda Roberts, Christine Brezden-Masley
On 15–16 June 2023, healthcare professionals and breast cancer patients and advocates from across Canada met in Toronto, Ontario, for the 2023 Canadian Breast Cancer Symposium (CBSC). The CBSC is a national, multidisciplinary event that occurs every 2 years with the goal of developing a personalized approach to the management of breast cancer in Canada. Experts provided state-of-the-art information
-
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from being able to prescribe optimal therapy. Eighteen Canadian oncology clinicians from the medicine, nursing
-
Large Language Models in Oncology: Revolution or Cause for Concern? Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Aydin Caglayan, Wojciech Slusarczyk, Rukhshana Dina Rabbani, Aruni Ghose, Vasileios Papadopoulos, Stergios Boussios
The technological capability of artificial intelligence (AI) continues to advance with great strength. Recently, the release of large language models has taken the world by storm with concurrent excitement and concern. As a consequence of their impressive ability and versatility, their provide a potential opportunity for implementation in oncology. Areas of possible application include supporting clinical
-
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi
Molecular analysis of the growing teratoma syndrome has not been extensively studied. Here, we report a 14-year-old boy with a growing mass during treatment for a mixed germ cell tumor of the pineal region. Tumor markers were negative; thus, growing teratoma syndrome was suspected. A radical resection via the occipital transtentorial approach was performed, and histopathological examination revealed
-
Demographic Analysis of Cancer Research Priorities and Treatment Correlations Curr. Oncol. (IF 2.6) Pub Date : 2024-03-29 Denis Horgan, Marc Van den Bulcke, Umberto Malapelle, Nicola Normanno, Ettore D. Capoluongo, Arsela Prelaj, Carmelo Rizzari, Aliki Stathopoulou, Jaya Singh, Marta Kozaric, France Dube, Manuel Ottaviano, Stefania Boccia, Gabriella Pravettoni, Ivana Cattaneo, Núria Malats, Reinhard Buettner, Karim Lekadir, Francesco de Lorenzo, Catherine Alix-Panabieres, Sara Badreh, Eric Solary, Ruggero De Maria, Paul
Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient Coalition (ECPC) and Childhood Cancer International-Europe (CCI-E) as part of the “UNCAN.eu” initiative, analyzed data from a comprehensive survey to explore
-
Deterioration of Performance Status during Palliative Radiotherapy Suggests a Significant Short Survival Duration: Indicating the Necessities for Considering Radiotherapy Discontinuation Curr. Oncol. (IF 2.6) Pub Date : 2024-03-27 Hitoshi Maemoto, Kazuaki Kushi, Isoko Owan, Takuro Ariga, Joichi Heianna, Akihiro Nishie
Discontinuation of palliative radiotherapy due to a patient’s declining general condition poses a clinical dilemma for palliative care physicians. This study aimed to investigate the survival duration of patients whose performance status (PS) deteriorated during palliative radiotherapy and inform decisions regarding early treatment discontinuation. We retrospectively analyzed data from patients referred
-
Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center Curr. Oncol. (IF 2.6) Pub Date : 2024-03-26 Sandra E. Díaz Casas, Juanita Martínez Villacrés, Carlos Lehmann Mosquera, Mauricio García Mora, Iván Mariño Lozano, Javier Ángel Aristizábal, Raúl Suarez Rodríguez, Carlos Alfonso Duarte Torres, Ricardo Sánchez Pedraza
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials
-
Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices Curr. Oncol. (IF 2.6) Pub Date : 2024-03-26 Julian Mangesius, Thomas Seppi, Christoph Reinhold Arnold, Stephanie Mangesius, Johannes Kerschbaumer, Matthias Demetz, Danijela Minasch, Samuel Moritz Vorbach, Manuel Sarcletti, Peter Lukas, Meinhard Nevinny-Stickel, Ute Ganswindt
This study aims to evaluate the clinical outcome of stereotactic radiosurgery as the sole treatment for brain metastases and to assess prognostic factors influencing survival. A total of 108 consecutive patients with 213 metastases were retrospectively analyzed. Treatment was determined with close-meshed MRI follow-up. Various prognostic factors were assessed, and several prognostic indices were compared
-
Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma Curr. Oncol. (IF 2.6) Pub Date : 2024-03-22 Kosuke Ueda, Keiichiro Uemura, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Hiroki Suekane, Hirofumi Kurose, Tasuku Hiroshige, Katsuaki Chikui, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Sachiko Ogasawara, Hirohisa Yano, Tsukasa Igawa
Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC. The expression of soluble programmed
-
Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review Curr. Oncol. (IF 2.6) Pub Date : 2024-03-21 Mohammad Abufaraj, Raghad Ramadan, Amro Alkhatib
Neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) that usually results in poor clinical outcomes and may be accompanied by paraneoplastic syndromes (PNS). NEPC is becoming more frequent. It can initially manifest as PNS, complicating diagnosis. Therefore, we reviewed the literature on the different PNS associated with NEPC. We systematically reviewed English-language
-
Meaningful Patient Engagement in Adolescent and Young Adult (AYA) Cancer Research: A Framework for Qualitative Studies Curr. Oncol. (IF 2.6) Pub Date : 2024-03-22 Niki Oveisi, Vicki Cheng, Dani Taylor, Haydn Bechthold, Mikaela Barnes, Norman Jansen, Helen McTaggart-Cowan, Lori A. Brotto, Stuart Peacock, Gillian E. Hanley, Sharlene Gill, Meera Rayar, Amirrtha Srikanthan, Mary A. De Vera
Over the last two decades, patient engagement in cancer research has evolved significantly, especially in addressing the unique challenges faced by adolescent and young adult (AYA) cancer populations. This paper introduces a framework for meaningful engagement with AYA cancer patient research partners, drawing insights from the “FUTURE” Study, a qualitative study that utilizes focus groups to explore
-
Complications and Recurrences after Excision and Reconstruction of Eyelid Tumours Curr. Oncol. (IF 2.6) Pub Date : 2024-03-22 Georgi Balchev
Introduction: The eyelids are a common site for skin tumours and account for 5–10% of all skin tumours. Treatment is mainly surgical and aims to preserve the anatomical structure of the eyelid, its function and not least its aesthetic appearance. Aim: Presentation of recurrence and complication rates of tumour-related eyelid surgery in a cohort of 450 tumours. Results: Analysis of a cohort of 450 tumours
-
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-03-21 Caroline Muñoz, Xiaochen Tai, Jessica Arias, Andrea Eisen, Munaza Chaudhry, Scott Gavura, Kelvin K. W. Chan
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Herceptin for adjuvant treatment of patients with HER2+ breast cancer. Methods: This was a population-based, retrospective study comparing the safety and
-
Utilization and Impact of a Radiation Nursing Clinic to Address Acute Care Needs for Patients with Gynecologic Cancers Curr. Oncol. (IF 2.6) Pub Date : 2024-03-21 Aaron Dou, Genevieve Bouchard-Fortier, Kathy Han, Michael Milosevic, Jelena Lukovic, Stephanie L’heureux, Xuan Li, Mary C. Doherty, Jennifer Croke
Background: The risk factors for acute care utilization in gynecologic oncology patients are poorly understood. This study aimed to evaluate risk factors for the utilization of our centre’s acute care radiation nursing clinic (RNC) by gynecologic oncology patients receiving radiotherapy (RT). Methods: This was a retrospective cohort study of gynecological cancer patients treated with RT at an academic
-
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort Curr. Oncol. (IF 2.6) Pub Date : 2024-03-21 Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly
-
PC-PEP, a Comprehensive Daily Six-Month Home-Based Patient Empowerment Program Leads to Weight Loss in Men with Prostate Cancer: A Secondary Analysis of a Clinical Trial Curr. Oncol. (IF 2.6) Pub Date : 2024-03-21 Wyatt MacNevin, Gabriela Ilie, Ricardo Rendon, Ross Mason, Jesse Spooner, Emily Chedrawe, Nikhilesh Patil, David Bowes, Greg Bailly, David Bell, Derek Wilke, Jeffery B. L. Zahavich, Cody MacDonald, Robert David Harold Rutledge
The Prostate Cancer—Patient Empowerment Program (PC-PEP) is a six-month daily home-based program shown to improve mental health and urinary function. This secondary analysis explores weight loss in male PC-PEP participants. Methods: In a randomized clinical trial with 128 men undergoing curative prostate cancer (PC) treatment, 66 received ‘early’ PC-PEP, while 62 were assigned to the ‘late’ waitlist-control
-
Personalized Radiation Therapy for Breast Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-03-20 Waqar Haque, Edward Brian Butler, Bin S. Teh
Breast cancer is diagnosed in nearly 3 million people worldwide. Radiation therapy is an integral component of disease management for patients with breast cancer, and is used after breast-conserving surgery or a mastectomy to reduce the risk of a local recurrence. The following review describes the methods used to personalize radiation therapy by optimizing patient selection, using advanced treatment
-
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers Curr. Oncol. (IF 2.6) Pub Date : 2024-03-20 David J. Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
Using digitized data from progression-free survival (PFS) and overall survival Kaplan–Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC
-
Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing Curr. Oncol. (IF 2.6) Pub Date : 2024-03-19 Alexandra Zara Rozalen, Jose Manuel Martin, Rithika Rajendran, Maneesh Jain, Victor E. Nava
Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most frequently as a mixed tumor combined with acinar adenocarcinoma. Although the histopathological features of DAP are well known, its genomic characteristics are still evolving, prompting the suggestion that all DAP would benefit from molecular analysis
-
Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective Curr. Oncol. (IF 2.6) Pub Date : 2024-03-19 Jason Agulnik, Goulnar Kasymjanova, Carmela Pepe, Jennifer Friedmann, David Small, Lama Sakr, Hangjun Wang, Alan Spatz, Khalil Sultanem, Victor Cohen
Background: The effect of COVID-19 on treatment outcomes in the literature remains limited and is mostly reported either as predictive survival using prioritization and modeling techniques. We aimed to quantify the effect of COVID-19 on lung cancer survival using real-world data collected at the Jewish General Hospital, Montreal. Methods: This is a retrospective chart review study of patients diagnosed
-
Perspectives on Ease of Use and Value of a Self-Monitoring Application to Support Physical Activity Maintenance among Individuals Living with and beyond Cancer Curr. Oncol. (IF 2.6) Pub Date : 2024-03-19 Manuel Ester, Meghan H. McDonough, Mannat Bansal, Julianna Dreger, Julia T. Daun, Margaret L. McNeely, Thompson Luu, S. Nicole Culos-Reed
Background: Physical activity (PA) can improve the physical and psychosocial health of individuals with cancer, yet PA levels remain low. Technology may address PA maintenance barriers in oncology, though the intervention effectiveness to date remains mixed. Qualitative research can reveal the nuances of using technology-based PA maintenance tools. The present study aimed to understand the perspectives
-
Wedge Resection versus Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors ≤8 mm Curr. Oncol. (IF 2.6) Pub Date : 2024-03-15 Arian Mansur, Zain Saleem, Jorind Beqari, Camille Mathey-Andrews, Alexandra L. Potter, James Cranor, Alexandra T. Nees, Deepti Srinivasan, Margaret E. Yang, Chi-Fu Jeffrey Yang, Hugh G. Auchincloss
The objective of this study was to evaluate the overall survival of patients with ≤8 mm non-small cell lung cancer (NSCLC) who undergo wedge resection versus stereotactic body radiation therapy (SBRT). Kaplan–Meier analysis, multivariable Cox proportional hazards modeling, and propensity score-matched analysis were performed to evaluate the overall survival of patients with ≤8 mm NSCLC in the National
-
Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma Curr. Oncol. (IF 2.6) Pub Date : 2024-03-15 Tasuku Nakabori, Sena Higashi, Yutaro Abe, Kaori Mukai, Toshiki Ikawa, Koji Konishi, Noboru Maeda, Katsuyuki Nakanishi, Shinichiro Hasegawa, Hiroshi Wada, Kazuyoshi Ohkawa
Various locoregional treatments for localized hepatocellular carcinoma (HCC) have been developed. This retrospective study investigated the safety and feasibility of combining on-demand selective locoregional treatment for residual lesions after tumor shrinkage (complete response [CR] oriented) or for solitary or few drug-resistant lesions (progressive disease (PD) salvage) with first-line atezolizumab
-
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE) Curr. Oncol. (IF 2.6) Pub Date : 2024-03-13 Natale Quartuccio, Salvatore Ialuna, Daniele Scalisi, Fabio D’Amato, Maria Rosa Barcellona, Maria Grazia Bavetta, Giorgio Fusco, Enrico Bronte, Emma Musso, Fabrizio Bronte, Viviana Picciotto, Antonio Carroccio, Francesco Verderame, Giuseppe Malizia, Angelina Cistaro, Fabio La Gattuta, Antonino Maria Moreci
The aim of this study was to present our preliminary experience with transarterial radioembolization (TARE) using Yttrium-90 (90Y), compare the cancer-specific survival (CSS) of patients with hepatocellular carcinoma (HCC) and colorectal cancer (CRC) liver metastases undergoing TARE, and investigate the influence of additional treatments on CSS. Our database was interrogated to retrieve patients who